A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Halozyme Therapeutics, Inc. HALO
Strong broader-coverage candidate · Halozyme Therapeutics, Inc.
On FrontierLab's discovery record since 2026-06-18 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-01), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 39.1% |
|---|---|
| Gross margin | 76.9% |
| Gross profits / assets | 0.43 |
| Rule of 40 | 96.1 |
| Net margin | 57% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 6.5 |
Quality checklist
- ✓ Revenue growth — 39.1% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.43 (pass ≥ 0.33)
- ✓ Gross margin — 76.9% (pass ≥ 60%)
- ✓ Cash generation
- ✓ Share dilution — -3%
Fundamentals — snapshot as of 2026-08-01
| Stage | Established |
|---|---|
| Share issuance (YoY) | -3% · buying back shares |
| Moat | — |
| TAM | — |
| P/E (trailing) | 29.7 |
| EPS (trailing) | $2.78 |
| Burn multiple | — |
| Gross-margin trend (pts) | -3.3 |
| Cash / assets | 0.12 |
| Net debt / EBITDA | 2.9 |
| Statements as of | Q1 FY2026 · filed 2026-05-11 |
Momentum context — a snapshot from 2026-08-01, not current
| Price at surface | $82.54 (as of 2026-08-01) |
|---|---|
| 52-week range | $58.53 – $84.44 |
| % off 52-wk high | -2.3% |
| RSI (14) | 65 |
| Relative volume | 0.8× |
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-01 (end-of-day). How grades are computed →